20+ years as cochlear implant surgeon and auditory neuroscientist

Titles:

• Ansin Foundation Chair in Otolaryngology, Massachusetts Eye and Ear (MEE) and Harvard Medical School
• Director, Pediatric Otology and Neurotology, Massachusetts Eye and Ear
• Program Director, Harvard Neurotology Fellowship
• Director, International Patient Services, Department of Otolaryngology, Massachusetts Eye and Ear
• Board Member, Auregen BioTherapeutics
• Former Chair, Clinical Advisory Board, Frequency Therapeutics
• Lead Consultant, 3NT Medical

Daniel Lee MD FACS is the Ansin Foundation Chair in Otolaryngology at the Massachusetts Eye and Ear (MEE) and Harvard Medical School. He is Director of Pediatric Otology and Neurotology, Program Director of the Harvard Neurotology Fellowship and Director of International Patient Services in the Department of Otolaryngology at MEE. He has extensive experience in the surgical restoration of hearing in pediatric and adult patients with cochlear implants, auditory brainstem implants, and bone conduction implants. He is a pioneer in the development and dissemination of minimally invasive endoscopic ear surgery techniques. He is known internationally for his work on the diagnosis and management of patients with superior canal dehiscence syndrome.

Dr. Lee’s basic and translational research group has been funded for two decades and seeks to 1) answer fundamental questions about central auditory processing and 2) improve auditory brainstem implant outcomes for patients with Neurofibromatosis Type 2 (NF2). His recent work has included pre-clinical studies of a conformable multichannel auditory brainstem implant electrode array in collaboration with the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Geneva, Switzerland. He has also secured several federally funded grants to develop endoscopic-assisted drug delivery technologies for treating inner ear disorders. 

Dr. Lee was chair of the Clinical Advisory Board at Frequency Therapeutics for nine years. Frequency went IPO in October of 2019 and focused on the development of small molecule therapy for hair cell regeneration to treat sensorineural hearing loss. Frequency completed a reverse merger with RNA-editing firm Korro Bio in 2023. He is currently on the Board of Directors of Auregen BioTherapeutics, a Cambridge-based company dedicated to the restoration of abnormal tissue using novel autologous cell-based tissue regeneration. Finally, Dr. Lee is a lead consultant for 3NT Medical, a company dedicated to the development of single-use endoscopes for minimally-invasive surgery.